Eli Lilly Raises Sales Outlook on Zepbound and Mounjaro Surge
Eli Lilly lifted its full-year sales forecast after strong Q3 demand for obesity drug Zepbound and diabetes treatment Mounjaro.
Eli Lilly raised its annual sales outlook after reporting another quarter of accelerating revenue from its two blockbuster injectable drugs, Zepbound and Mounjaro, signaling continued momentum in the rapidly expanding weight-loss and diabetes treatment market.
The Indianapolis-based pharmaceutical giant said sales of Zepbound, its GLP-1 receptor agonist approved for obesity, and Mounjaro, the related compound targeting Type 2 diabetes, surged through the third quarter, driving the upward revision to guidance. Both drugs belong to the same class of incretin-based therapies that have reshaped the metabolic disease landscape.
Read more High Diesel Costs Push Small Trucking Firms Toward Bankruptcy →
Chief Executive David Ricks indicated that the obesity drug market still has substantial room to grow, describing the potential for "dramatic" expansion as millions of eligible patients remain untreated globally. His comments reinforce a broader industry view that GLP-1 therapies are still in the early stages of widespread adoption despite the billions in revenue they have already generated.
The updated outlook adds to a string of positive quarterly results for Lilly, which has invested heavily in manufacturing capacity to meet surging prescription demand. Supply constraints have previously limited the company's ability to fully capitalize on physician and patient interest in both products.
Analysts will be watching whether Lilly can sustain its growth trajectory as rival Novo Nordisk competes for market share with its own GLP-1 portfolio, including Ozempic and Wegovy, and as newer entrants begin clinical development. Continue reading at Business News.
